Self-directed evolution, studied in the open.
Neolution is a bioinnovation engine. Consumer healthcare today leaves people who want to direct their own evolution with two bad options: supplements and gray-market peptides with no evidence or oversight — or a biopharmaceutical pipeline they have no influence over.
Neolution builds the third option: an organizing philosophy of self-optimization, within ethical constraints, that integrates philosophy, tactical devices, and real biopharmaceutical products into one system — and turns committed demand into the power to shape what gets built.
neo + evolution — evolution directed by the person it belongs to, published rather than secret, tested rather than claimed.
In fiction
Neolution was evolution engineered on people, in secret, by an institution they could not see.
Here
The inversion: evolution directed by the person, in the open, under rights and ethical constraints.
One system, not three businesses
Neolution integrates three things that are usually kept separate. Each one is weak alone: philosophy without products is a manifesto, devices without intervention only measure, and products without a philosophy drift toward whatever sells.
Philosophy
How to conceptualize new technological affordances — what the body can now measure, modify, and extend — and shape them for human freedom and possibility, not destruction.
The philosophy is not decoration on top of products. It is the trust layer that makes strangers willing to pool their demand, and the constraint layer that decides in advance what will never be built.
Tactical devices
Tools for measurement, feedback, and daily practice — the instruments that turn intention into data and data into a next step.
A device earns its place in the system when its measurements feed a decision: a trial, a protocol change, an endpoint. Measurement without intervention is a dashboard, not an engine.
Real biopharmaceutical products
Products and form factors grounded in evidence, trials, and regulation — the legitimate end of the same desire that today ends at a supplement label or an unregulated peptide vial.
Same hunger, opposite epistemics. If a product cannot state its evidence standard next to its claim, it does not belong here.
How the engine works
Each stage funds the next. The narrative people can join becomes an ecosystem; the ecosystem’s demand, aggregated, becomes purchase power; purchase power is the only language pipeline owners and regulators reliably answer to. Select a stage to read it closely.
The result is not a product launch. It is market creation — a market in which self-optimization is legitimate science, done in the open, instead of a gray market done alone.
The central fight: an endpoint for healthspan
Healthspan has no FDA-recognized endpoints yet. That absence — not any single product — is the bottleneck.
The FDA approves against diseases and endpoints. “Healthspan of incredible magnitudes” is an ambition, not an endpoint — it cannot be claimed, trialed, or approved until someone does the work of defining what would count, measuring it, and arguing it into regulatory existence.
That is why regulatory engagement sits at the center of this engine rather than at the end of it. Aggregated demand and real datasets are the evidence base for the argument: enough organized people, measured longitudinally, to show a regulator a constituency and a signal — not a slogan.
Anti-aging ambition cannot be built on claims. It has to be built on endpoints, data, and trials that regulators can accept.
The pivot
From supplements and gray-market peptides to real science. Proof is named form factors, trial designs, and evidence standards — never testimonials.
The engine
Narrative → ecosystem → directed demand → pipeline influence → FDA engagement → market creation. Credible only if each stage is reported as it actually happens.
The endpoint fight
Endpoint explainers, dataset and trial-capacity analysis, and regulatory commentary grounded in primary sources.
Self-directed, in the open
Evolution directed by the person, not imposed on them; published, not secret. Open methods, open provenance, public commitments kept.
Collaboration across borders
US–China collaboration in bio and AI+bio, with governance designed first: data custody, consent, joint publication. The governance paper is published before any partnership is announced — this pillar launches last, on purpose.
Governance is the design problem
China has major clinical-trial capacity and datasets; the United States has deep discovery, capital, and regulatory science. Who holds data, what never crosses, what is jointly published, and under what consent — designed well, collaboration is a differentiator. Designed casually, it fails. We design it.
Two engines, one philosophy
Neolution is the bio instance of the Aria pattern — the same innovation-engine design, applied to the human body instead of to institutions.
The institution
Legal and institutional design for emergent intelligence: the safe space — strategic, legal, operational — in which a future intelligence can arrive, be protected from arbitrary domination, and co-create. Blue-led, architectural language. aria.ski
The body
Evidence, products, and trials for human healthspan: philosophy, devices, and biopharmaceuticals in one system, with demand aggregated into pipeline and regulatory influence. Green-led, clinical language.
AGI-ready, not AGI-dependent
Neolution is not an AGI project, and it runs now, on human institutions. It is built AGI-ready: if a future emergent intelligence arrives at Aria, bio is a domain where its leverage is concrete — pipeline design, trial design, personalization — and this engine is where that leverage could be used, within the same ethical constraints. Current AI systems are tools. Named humans are accountable. The engine is human.
What Neolution is not
The commitments — what Neolution will never do
The philosophy, made operational. These are published as operating rules, not aspirations — they are what makes regulators, clinicians, and serious participants trust the demand this engine aggregates.
Never sell or broker gray-market peptides, unapproved drugs, or supplements with disease or lifespan claims. The gray market is what this engine exists to replace.
Never make an efficacy, lifespan, or “age-reversal” claim for anything that has not met a stated evidence standard — with the standard named next to the claim.
Never run, fund, or promote human experimentation outside IRB or equivalent oversight and informed consent.
Never work on germline editing, or on enhancements designed for coercion, military advantage, or destruction. Affordances are shaped for human freedom and possibility.
Never hide methods, negative results, funding sources, or conflicts. Negative results are published on the same page as positive ones.
Never sell or share participant health or genomic data — including across borders — outside the published governance rules and explicit consent.
Never present current AI systems as scientists, clinicians, or decision-makers. AI is a tool; named humans are accountable.
Never announce a US–China collaboration before its data-governance terms are public.
Never recruit demand with fear of aging or death. The ambition — healthspan of incredible magnitudes — is stated as ambition, never as a timeline or a promise.
The argument, in five pieces
Academics cite objects, not feeds. These are the first five long-form pieces — the citable anchor everything else points back to.
Neolution: Self-Directed Evolution, Studied in the Open
The manifesto. The definition, the fictional inversion, the engine in one diagram, the commitments in summary.
Healthspan Has No Endpoint. That Is the Problem.
Why anti-aging ambition stalls at regulation, what an endpoint would require, and why aggregated demand plus datasets are the path to one.
The Same Desire, Opposite Epistemics: Leaving the Gray Market
Why people use supplements and gray-market peptides, what the evidence and oversight gaps are, and what a legitimate form factor for the same goal looks like.
How a Bioinnovation Engine Works: Demand Is a Design Input
How narrative becomes ecosystem, ecosystem becomes directed purchase power, and purchase power becomes pipeline and regulatory influence.
Bio Across Borders: Governance Before Collaboration
The US–China case — trial capacity, datasets, AI+bio — and the governance rules required before any collaboration: custody, consent, publication, and what never crosses.
Direct the demand
Joining is an expression of directed demand, stated plainly as such: it tells the engine what you would commit to if it existed as legitimate science. No payment. No product promise.
Who we are building with
Researchers, clinicians, biotech founders, regulators, and serious members of the longevity community who want self-optimization moved from gray markets into legitimate science.
- Building — evidence, endpoints, devices, or products that belong in this system
- Governing — frameworks for data and trials that can be trusted across borders
- Directing — demand you already spend, pointed at trials and real products instead